Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QGEN 
Qiagen NV (QGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: QGEN (1-star) is a SELL. SELL since 1 days. Profits (8.80%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $52.39
1 Year Target Price $52.39
| 6 | Strong Buy |
| 3 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.45% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.08B USD | Price to earnings Ratio 27.51 | 1Y Target Price 52.39 |
Price to earnings Ratio 27.51 | 1Y Target Price 52.39 | ||
Volume (30-day avg) 16 | Beta 0.64 | 52 Weeks Range 37.43 - 51.88 | Updated Date 08/29/2025 |
52 Weeks Range 37.43 - 51.88 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.54% | Basic EPS (TTM) 1.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When After Market | Estimate 0.6 | Actual 0.6 |
Profitability
Profit Margin 18.3% | Operating Margin (TTM) 25.49% |
Management Effectiveness
Return on Assets (TTM) 9.01% | Return on Equity (TTM) 10.81% |
Valuation
Trailing PE 27.51 | Forward PE 19.08 | Enterprise Value 10494954171 | Price to Sales(TTM) 4.94 |
Enterprise Value 10494954171 | Price to Sales(TTM) 4.94 | ||
Enterprise Value to Revenue 5.14 | Enterprise Value to EBITDA 14.68 | Shares Outstanding 216834000 | Shares Floating 214888999 |
Shares Outstanding 216834000 | Shares Floating 214888999 | ||
Percent Insiders 1.61 | Percent Institutions 87.47 |
Upturn AI SWOT
Qiagen NV
Company Overview
History and Background
Qiagen NV was founded in 1984 in Du00fcsseldorf, Germany, by Detlev Riesner and Ju00fcrgen Schumacher as a spin-off from Heinrich Heine University. Initially focused on RNA extraction, Qiagen has grown through innovation and acquisitions to become a global provider of sample to insight solutions.
Core Business Areas
- Molecular Diagnostics: Develops and markets diagnostic solutions for human healthcare, including infectious disease testing, oncology diagnostics, and companion diagnostics.
- Life Science Research: Offers a wide range of products and services for genomics, proteomics, and cell biology research, enabling scientists to extract, purify, and analyze DNA, RNA, and proteins.
- Applied Testing: Provides solutions for use in applied testing markets, such as forensics, veterinary diagnostics, and food safety.
Leadership and Structure
The current CEO is Thierry Bernard. Qiagen has a global organizational structure with regional headquarters and operations around the world. Their leadership consists of the Management Board and Supervisory Board.
Top Products and Market Share
Key Offerings
- QIAseq Portfolio: Comprehensive solutions for next-generation sequencing (NGS) library preparation and data analysis. Competitors include Illumina (ILMN), Roche (RHHBY), and Thermo Fisher Scientific (TMO). Market share is not directly published for this specific product, but it's a significant contributor to Qiagen's NGS revenues.
- QuantiFERON-TB Gold Plus: An in-vitro diagnostic test for tuberculosis infection, offering high accuracy and ease of use. Competitors include Diasorin (Diasorin) and Oxford Immunotec (TMO acquired). Qiagen is a leader in this space.
- NeuMoDx Molecular Systems: Automated, high-throughput molecular diagnostics systems used for a variety of diagnostic assays. Market Share data isn't specific per product, but Qiagen has a significant share in this market. Competitors include Roche, Abbott (ABT), and Siemens Healthineers (SIEMENS-HEALTHCARE).
Market Dynamics
Industry Overview
The molecular diagnostics and life science research markets are characterized by increasing demand for personalized medicine, advanced genomics, and automation. The industry is competitive, with a mix of large multinational corporations and smaller specialized companies.
Positioning
Qiagen NV is a leading player in the molecular diagnostics and life science research markets. The company's strength lies in its sample preparation technologies and its expanding portfolio of diagnostic assays. Qiagen's competitive advantage is derived from its comprehensive 'sample to insight' solutions and innovation.
Total Addressable Market (TAM)
The total addressable market for Qiagen NV's products is estimated to be in the tens of billions of dollars. Qiagen is well-positioned to capture a significant share of this market due to its broad product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive product portfolio
- Global distribution network
- Leading position in sample preparation
- Innovation in molecular diagnostics
Weaknesses
- Reliance on acquisitions for growth
- Competition from larger players
- Potential for pricing pressure
- Exposure to regulatory changes
Opportunities
- Expanding into emerging markets
- Developing new diagnostic assays
- Collaborating with pharmaceutical companies
- Leveraging NGS technologies
- Growing demand for personalized medicine
Threats
- Economic downturns
- Technological advancements by competitors
- Changes in healthcare regulations
- Intellectual property infringement
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- RHHBY
- ABT
Competitive Landscape
Qiagen NV faces intense competition from larger companies with broader product portfolios. However, its focus on sample preparation and specialized diagnostic assays provides a competitive advantage.
Major Acquisitions
Exiqon
- Year: 2016
- Acquisition Price (USD millions): 160
- Strategic Rationale: Strengthen Qiagen's position in miRNA-based research and diagnostics.
NeuMoDx
- Year: 2020
- Acquisition Price (USD millions): 248
- Strategic Rationale: Expanding Molecular Diagnostics portfolio
Growth Trajectory and Initiatives
Historical Growth: Qiagen NV has experienced consistent growth over the past several years, driven by acquisitions and organic growth in its core business areas.
Future Projections: Analyst estimates project continued growth for Qiagen NV, driven by its strong market position and expanding product portfolio.
Recent Initiatives: Qiagen NV has recently focused on expanding its molecular diagnostics portfolio, investing in NGS technologies, and streamlining its operations.
Summary
Qiagen is a strong player in the molecular diagnostics and life science research markets, known for its sample preparation technologies and expanding diagnostic assays. Recent financial performance shows revenue growth, but competitive pressures and economic factors remain concerns. Its strategic initiatives focus on NGS and diagnostic portfolio growth. Qiagen's innovation and market positioning make it a competitive player, despite challenges posed by larger rivals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qiagen NV
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-06-28 | CEO, MD & Member of Management Board Mr. Thierry Bernard | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 5700 | Website https://www.qiagen.com |
Full time employees 5700 | Website https://www.qiagen.com | ||
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.